Science abstracts on Digestive & Bowel Disorders
- CBD in inflammatory bowel diseases: a brief overview
- Cannabis finds its way into treatment of Crohn’s disease
- CBD reduces intestinal inflammation through the control of neuroimmune axis
- Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis
- The effects of Delta-tetrahydrocannabinol and CBD alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis
- Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice
- Cannabinoids and the gut: New developments and emerging concepts
- Endocannabinoids and the gastrointestinal tract
- Cannabinoids and gastrointestinal motility: Animal and human studies
- Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis
- Manipulation of the endocannabinoid system in colitis: A comprehensive review
- Low-dose cannabidiol is safe but not effective in the treatment for Crohn's Disease, a randomized controlled trial
- Cannabidiol in inflammatory bowel diseases: A brief overview
- CBD reduces intestinal inflammation through the control of neuroimmune axis
- Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
- Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
- Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease
- Endocannabinoids and the gastrointestinal tract
- CBD and gastrointestinal motility
- Getting into the weed: the role of the endocannabinoid system in the brain-gut axis
- Cannabinoids and GI disorders: Endogenous and exogenous
